Welcome to our dedicated page for Artelo Bioscienc SEC filings (Ticker: ATLEW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for ARTELO BIOSCIENCES WTS 25 (ATLEW) provides access to regulatory documents filed by Artelo Biosciences, Inc., the Nevada corporation associated with these warrants. The company reports material events under the Securities Exchange Act of 1934, including current reports on Form 8-K that describe offerings of common stock and pre-funded warrants, as well as underwriting arrangements and over-allotment options.
In one Form 8-K, Artelo Biosciences, Inc. details an underwriting agreement with R. F. Lafferty & Co., Inc. for an underwritten offering of common stock and pre-funded warrants, the pricing of those securities, and the partial exercise of a 45-day over-allotment option. The filing notes that the offering closed and that the company delivered the securities to the underwriter, and it specifies the resulting gross and net proceeds. Disclosures like these help investors understand how the company issues equity and related instruments that form the context for ATLEW.
On this page, you can review such filings as they appear in the SEC’s EDGAR system, with AI-powered summaries that explain the key points of each report in plain language. These summaries highlight material terms in documents such as Form 8-K, making it easier to identify information about capital-raising transactions, warrant issuances, and changes in the company’s capital structure. The platform also tracks new filings as they become available, so users can see updates related to Artelo Biosciences, Inc. and securities connected to ATLEW.
Use this page to quickly navigate Artelo Biosciences, Inc.’s filings, understand the disclosures that affect its common stock and warrant instruments, and interpret complex regulatory language through AI-generated insights.
Artelo Biosciences approved a 3-for-1 reverse stock split of its common stock, combining each three existing shares into one new share. The split is intended to increase the share price to improve marketability and liquidity, with trading on a split-adjusted basis starting March 10, 2026.
No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share instead. The company expects approximately 708,258 shares of common stock to be issued and outstanding immediately after the reverse split, and all outstanding warrants and other derivatives will adjust automatically under their terms.
Artelo Biosciences, Inc. is a Nevada‑incorporated, clinical‑stage biopharmaceutical company based in Solana Beach, California, focused on therapeutics that modulate lipid‑signaling pathways, including the endocannabinoid system.
The company’s pipeline includes three main programs. ART27.13, a dual CB1/CB2 agonist in a Phase 1b/2a Cancer Appetite Recovery Study (CAReS), targets cancer‑related anorexia. In an interim Phase 2a analysis, patients titrated to 1,300 micrograms showed mean weight gain of about 6%, while placebo patients lost weight, with supportive trends in lean body mass and activity and a generally favorable safety profile.
ART26.12, a FABP5 inhibitor, completed a first‑in‑human Phase 1 single‑ascending‑dose study in healthy volunteers, showing only mild, transient adverse events and dose‑dependent, linear pharmacokinetics, supporting further development in chemotherapy‑induced peripheral neuropathy and other potential indications. ART12.11, a proprietary CBD/TMP cocrystal, has patent protection to 2038 and is being advanced preclinically for anxiety and other disorders, with nonclinical evidence of improved pharmacokinetics versus conventional CBD. Artelo holds worldwide exclusive licenses on ART27.13 and ART26.12, maintains an expanding patent estate around all three candidates, operates under extensive U.S. and international regulatory frameworks, and reported seven employees as of December 31, 2025.
Artelo Biosciences director Connie Matsui reported receiving a grant of stock options on January 30, 2026. The award covers 292 stock options, each with a $1.71 exercise price, giving the right to buy 292 shares of common stock. The options were granted at no cost and are held directly, with 292 derivative securities beneficially owned after the transaction. Vesting is contingent on Matsui continuing as a Service Provider, with all shares vesting on the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date.
Artelo Biosciences, Inc. director Blayney Douglas received an award of stock options covering 292 shares of common stock at an exercise price of $1.71 per share. The options expire on January 30, 2036 and are held directly.
According to the grant terms, all 292 option shares vest in full if Douglas continues as a service provider until the earlier of the one-year anniversary of the vesting commencement date of January 30, 2026 or the day before the next annual stockholder meeting following that date. After this grant, he beneficially owns 292 derivative securities.
Artelo Biosciences director Emanuele Robert Martin received a small stock option grant. On January 30, 2026, he was awarded options to buy 292 shares of Artelo Biosciences common stock at an exercise price of
According to the terms, all 292 options vest in a single tranche, provided he continues as a service provider. Vesting occurs on the earlier of the one-year anniversary of the vesting commencement date of January 30, 2026, or the day before the next annual stockholder meeting following that date.
Artelo Biosciences director Kelly Steven received a new stock option grant. On January 30, 2026, Steven was awarded stock options to purchase 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, with no purchase price for the option itself.
The options vest in full if Steven continues as a service provider until the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the company’s next annual stockholder meeting after that date. After this grant, Steven beneficially owns 292 derivative securities directly.
Artelo Biosciences director Tamara A. Favorito reported a new stock option grant on Common Stock. On January 30, 2026, she was awarded stock options to purchase 292 shares at a conversion or exercise price of
All 292 options vest in full once, subject to her continuing as a service provider, on the earlier of the one-year anniversary of the January 30, 2026 vesting commencement date or the day before the next annual stockholder meeting following that date. After this grant, she beneficially owns 292 derivative securities directly.
Artelo Biosciences director Gregory Reyes received a small stock option grant. On January 30, 2026, he was awarded options to buy 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, held directly. These options vest 100% on the earlier of January 30, 2027 or the day before the next annual shareholder meeting, as long as he continues serving the company.
ARTELO BIOSCIENCES, INC. reported that its Chief Financial Officer, Mark Edward Spring, received a grant of stock options on January 29, 2026. The grant covers 36,391 stock options with an exercise price of $1.68 per share.
These options vest over four years, starting from a vesting commencement date of January 1, 2026. One forty-eighth of the option shares vests each month, so the award becomes fully vested on the four-year anniversary of that commencement date, as long as he continues as a service provider.
Artelo Biosciences reported a Form 4 insider transaction for President, CEO, CFO, Treasurer and Secretary Gregory D. Gorgas. He was granted 154,713 stock options on January 29, 2026 with an exercise price of $1.68 per share and expiration on January 29, 2036.
These options vest in equal monthly installments, with 1/48 of the shares vesting each month starting from a vesting commencement date of January 1, 2026, so long as he continues as a service provider. The entire grant is scheduled to be fully vested after four years.